Johnson & Johnson

NYSE:JNJ  
164.87
-0.38 (-0.23%)
5:15:32 PM EDT: $164.87 0.00 (0.00%)
Products, Strategic Combinations

Dyadic Announces Agreement With Janssen For Manufacture Of Therapeutic Protein Candidates Using Its C1 Platform

Published: 12/17/2021 13:53 GMT
Johnson & Johnson (JNJ) - Dyadic Announces Research, License and Collaboration Agreement With Janssen for Manufacture of Therapeutic Protein Candidates Using Its C1 Platform.
Dyadic International Inc- Janssen Will Pay Dyadic an Upfront Payment of $500,000 for Non-exclusive Rights to Utilize C1 Platform.
Dyadic International Inc- Janssen Will Provide Research and Development Funding Up to EUR 1.6 Million to Develop and Assess C1 Production Cell Lines for Its Product Candidates.
Dyadic International Inc- Janssen Has Option to Pay a Mid-seven Figure Payment for an Exclusive License From Dyadic to Use C1 Platform.
Dyadic International Inc- Upon Successful Completion of Technology Transfer, Dyadic is Eligible to Receive a Milestone Payment in Low Seven Figures.